Posts by Zachary S. Wallace, MD, MSc
The Mass General Rheumatology Vasculitis Program: Q&A With Drs. Sebastian Unizony and Zachary Wallace
The Rheumatology Vasculitis Program at Massachusetts General Hospital provides state-of-the-art care to patients with vasculitis, educates peers, and creates a platform for innovative research. Co-Directors Sebastian Unizony, MD, and Zachary Wallace, MD, MSc, discuss the program and new Vasculitis Patient Conference.
Illness-related Uncertainty Correlates With Mental Health in Patients With Systemic Autoimmune Diseases
Zachary S. Wallace, MD, MSc, Daniel L. Hall, PhD, and colleagues found associations between illness-related uncertainty and psychologic health in patients with systemic autoimmune rheumatic diseases, and the measures varied according to type of disease.
Anti-CD20 Monoclonal Antibody Therapy for Immune-mediated Diseases Increases Risk of Death from COVID-19
Zachary S. Wallace, MD, MSc, Naomi J. Patel, MD, and colleagues determined retrospectively that the risk of death from COVID-19 is twice as high in patients who use anti-CD20 monoclonal antibodies for the treatment of immune-mediated diseases versus COVID-19 patients in the general population.
The Role of Immunosuppressives in Breakthrough COVID-19 Infections Among Rheumatic Patients
Zachary S. Wallace, MD, MSc, at Massachusetts General Hospital has been tracking breakthrough COVID-19 infections among vaccinated patients with rheumatic diseases. He and Mass General Brigham colleagues have observed that those with breakthrough infections are having an inadequate immune response to the vaccines.
Use of Rituximab, JAK Inhibitors at Time of COVID-19 Onset Increases Poor Outcomes
In a registry study of 2,869 patients with rheumatoid arthritis and COVID-19, Mass General Brigham researchers and colleagues found that use of rituximab or JAK inhibitors at the time of COVID-19 onset was associated with worse COVID-19 outcomes than for patients using tumor necrosis factor-α inhibitors.
Using AI and Provider Notes to Study Anti-Neutrophil Cytoplasmic Antibody–Associated Vasculitis
Zachary S. Wallace, MD, MSc, of the Rheumatology Unit, and colleagues have demonstrated proof of concept that automated text mining of narrative chart notes is a feasible tool for studying the natural history of anti-neutrophil cytoplasmic antibody–associated vasculitis.
Case Series: COVID-19 Patients with Rheumatic Disease Can Develop SARS-CoV-2 Antibodies
Kristin M. D'Silva, MD, and Zachary S. Wallace, MD, MSc, of the Rheumatology Unit, report that 10 out of 13 patients (77%) who had a rheumatic disease and COVID-19, and subsequently underwent SARS-CoV-2 antibody testing, had detectable antibodies.
Case Series: Tocilizumab and Tofacitinib for Resolved Hepatitis B Infection
No episodes of hepatitis B virus (HBV) reactivation occurred with tocilizumab or tofacitinib treatment over three to four years of follow-up in a small case series of patients with resolved HBV from a U.S. health care system.
Risk of Respiratory Failure Tripled in COVID-19 Patients with Existing Rheumatic Disease
Massachusetts General Hospital clinicians find that patients with rheumatic disease who develop COVID-19 need close monitoring.
First Classification Criteria Developed for IgG4–Related Disease
The American College of Rheumatology and the European League Against Rheumatism that includes Massachusetts General Hospital physicians have developed and validated classification criteria for IgG4–related disease in a large cohort of patients.
Zachary Wallace, MD, MS, is a graduate of Cornell University and Georgetown University School of Medicine. He completed his medicine residency and rheumatology fellowship at Massachusetts General Hospital. During fellowship, he completed a Masters of Science in Epidemiology at the Harvard T.H. Chan School of Public Health. Following fellowship, he joined the Rheumatology Unit in the Division of Rheumatology, Allergy and Immunology. In addition to seeing patients in the Rheumatology Clinic and the Rheumatology-Dermatology Clinic, Dr. Wallace receives grant funding to conduct clinical epidemiology research in IgG4-related disease (IgG4-RD) and ANCA-associated vasculitis (AAV). His clinical interests include IgG4-RD as well as AAV. He is a member of the Center for IgG4-Related Disease at Mass General as well as the Vasculitis and Glomerulonephritis Center at Mass General.